Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
May 29, 2020
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
Apr 22, 2020
FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments
Apr 16, 2020
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
Apr 09, 2020
Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers
Apr 08, 2020
OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic
Mar 09, 2020
Insights on Triple-Negative Breast Cancer - Approval and Subsequent Uptake of New Targeted Therapies and Immunotherapies Driving Growth
Jan 31, 2020
Breast Cancer Drug Market & Clinical Trial Insights, 2025 - Drug Trials, Pricing, Dosage, Cancer Prevalence, Patent Information
Dec 30, 2019
METAvivor Announces 2019 Grant Awards For Metastatic Breast Cancer Research
Dec 05, 2019
OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO(TM) and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Dec 04, 2019
Global Breast Cancer Diagnostic, Drug Technologies & Markets, 2024 - Therapeutics by HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors and Hormone Receptors
Nov 20, 2019
Phoenix Molecular Designs Initiates its Phase 1/1b Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer
Nov 14, 2019
Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®
Nov 12, 2019
OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO(TM) KEYNOTE Studies Evaluating Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Nov 12, 2019
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019
Nov 05, 2019
Anixa Biosciences Announces Patent Issued for its Breast Cancer Vaccine
Nov 05, 2019
Lumicell Initiates Pivotal Trial for Breast Cancer Surgical Guidance Solution
Oct 23, 2019
Envisagenics wins another SBIR grant from the National Cancer Institute to enhance their AI/ML platform for Immunotherapy development
Oct 02, 2019
Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer (TNBC)
Sep 28, 2019
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer